Precision BioSciences Announces Late-Breaking Oral Presentation for PBGENE-HBV at AASLD The Liver Meeting 2026
Business Wire•08/10/2026•07:01 ET
0
Key Highlights
- ➤Late-breaking oral presentation selected for PBGENE-HBV at AASLD The Liver Meeting 2026
- ➤PBGENE-HBV targets cccDNA, the sole source of hepatitis B viral replication
- ➤Phase 1 ELIMINATE-B trial enrolling HBeAg-positive and negative chronic hepatitis B patients
- ➤FDA granted PBGENE-HBV Fast Track designation
- ➤Presentation title cites durable pgRNA loss supporting a path toward viral cure
Precision BioSciences Announces Late-Breaking Oral Presentation for PBGENE-HBV at AASLD The Liver Meeting 2026
Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for high unmet need diseases, today announced that it has been selected to deliver a late-breaking oral presentation at The Liver Meeting 2026, the 77(th) annual meeting of the American Association for the Study of Liver Diseases (AASLD). The Liver Meeting 2026 will take place November 5-9 in Denver, CO.
Get started
Create a free account to read the full story.